Biopharmaceutical IndustryRoche’s Genentech unit is taking global rights to HM17321 outside South Korea, while Hanmi completes the ongoing phase 1 study before Genentech assumes later development. Strategically, the deal broadens Roche’s obesity portfolio beyond GLP-1 and GIP programs toward body-composition claims that next-generation obesity developers increasingly want to own.
Michael Torres·Aug 24, 2026
Biopharmaceutical IndustryPatients treated with Keytruda plus intismeran autogene lived longer without recurrence than patients on Keytruda alone in the Phase 3 INTerpath-001 study. For Merck, the significance is broader than one melanoma readout: it adds a new potential revenue stream as the company prepares for Keytruda’s patent slide starting in 2028.
Michael Torres·Aug 22, 2026 
Healthcare InvestmentThe argument is that investors and regulators are still willing to back pediatric rare cancer programs when biology, endpoints, and patient need are tightly aligned. The February renewal of the pediatric rare disease priority review voucher, after a lapse at the end of 2024, is presented as a key policy support for that thesis.
Michael Torres·Aug 20, 2026 
Regulatory & PolicyThe Council on Education for Public Health has not finalized its next competency framework, but draft changes have already exposed a dispute over whether public health education is adapting to varied legal environments or preemptively retreating from explicit language on racism. The outcome matters beyond curriculum design because accreditation standards determine what dozens of schools and nearly two hundred programs must demonstrate in order to keep their standing.
Michael Torres·Aug 19, 2026 
Biopharmaceutical IndustryA full commercial quarter after Eli Lilly’s April approval of Foundayo, early sales show Novo Nordisk ahead in the oral obesity market. The sources point to a familiar obesity rivalry taking a different shape in pills: Novo holds the early edge on brand recognition and reported weight-loss data, while Lilly’s simpler dosing and lower-cost small-molecule manufacturing could matter more as the market broadens.
Michael Torres·Aug 19, 2026 
Regulatory & PolicyA lawsuit filed in the U.S. District Court in Massachusetts challenges the Trump administration’s plan to replace duration of status with a fixed visa period for many international students and postdoctoral researchers. The case turns on whether DHS lawfully justified a rule change that plaintiffs say could affect more than two million nonimmigrants annually and weaken the U.S. research base.
Michael Torres·Aug 19, 2026 
Regulatory & PolicyThe White House’s new toolkit marks a clear policy break from the Biden administration’s “housing first” and harm reduction approach. For providers and local governments, the practical signal is that federal support is being steered toward recovery models built around treatment, structure, and abstinence rather than unconditional housing access.
Michael Torres·Aug 14, 2026 
Regulatory & PolicyBioSpace’s review of the sector points to a market moving from theory toward execution. Recent late-stage data in treatment-resistant depression and major depressive disorder, alongside actions by the Trump administration and the FDA, have improved the setup for developers even as safety, abuse risk and care-delivery constraints remain unresolved.
Michael Torres·Aug 10, 2026 
Healthcare InvestmentThe California cardiovascular biotech increased both the size and price of its offering, moving to 21.2 million shares at $18 apiece from an earlier range of $15 to $17 for 17.5 million shares. The proceeds are aimed at advancing BHB-1893 into Phase 3 development in hypertrophic cardiomyopathy, where Braveheart wants to compete with Bristol Myers Squibb’s Camzyos and Cytokinetics’ Myqorzo.
Michael Torres·Aug 9, 2026 
Regulatory & PolicyIn a rapidly evolving legal landscape, the Department of Justice has now obtained settlements from a third clinic over matters related to transgender healthcare services. Against the backdrop of high-profile legal cases and political debate—including actions against the U.S. organ donor network and the ongoing saga of Anthony Fauci—this article explores the implications of increased federal scrutiny and enforcement activity surrounding trans healthcare, compliance requirements, and the broader regulatory environment.
Michael Torres·Aug 7, 2026 
AI in Drug DiscoveryIn a notable stride for AI-driven health technology, QuantHealth has secured $45 million in Series B funding to further develop its simulation platform for clinical trials. By offering pharmaceutical companies predictive insights before real-world patient enrollment, QuantHealth is positioning itself as a solution to pervasive challenges within clinical development, such as elevated trial failure rates and sluggish time-to-market for new therapeutics.
Michael Torres·Aug 5, 2026 
Regulatory & PolicyAs scrutiny on drug pricing intensifies, a recent study argues that the federal exemption allowing orphan drugs to avoid Medicare price negotiations may not be warranted in all cases. Policymakers, industry, and patients face difficult questions about balancing incentives for rare disease drug development with controlling public health spending.
Michael Torres·Aug 4, 2026 